Oncopeptides publishes Q3 2021 report

Back to the futureSTOCKHOLM — November 24, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the third quarter 2021. Financial overview July-September · Net sales amounted to SEK 54.3 M (0.0) · Operating loss amounted to SEK 338.9 M (loss: 383.5) · Loss for the period was SEK 777.5 M (loss: 383.4) · Loss per share, before and after dilution, was SEK 10.33 (loss: 5.71) · Cash and cash equivalents amounted to SEK 671.3 M (